UK – UK trial evaluating ‘mix and match’ COVID-19 vaccine regimens expanded

A UK trial evaluating the safety of mixing different COVID-19 vaccines is set to be expanded to include Moderna and Novavax’s respective jabs.

The Com-Cov study, announced earlier this year, is the first trial in the world to evaluate the effects of using different COVID-19 vaccines for the first and second dose within a two-dose vaccination regimen.

It is designed to monitor the impact of the different dosing regimens on immune responses. It is being run by the National Immunisation Schedule Evaluation Consortium (NISEC) across eight National Institute for Health Research (NIHR) supported sites.

Researchers will gather immunological evidence on different intervals between the first and second dose for a mixed-vaccine regimen against control groups when the same vaccine is used for both doses…